Disparities in Accessing CAR-T and Bispecific Antibody Therapies | Craig Cole, MD | EHA 2025

 At EHA 2025, Dr. Craig Cole sheds light on the urgent issue of disparities in access to CAR-T cell therapies and bispecific antibodies for patients with multiple myeloma. Despite their transformative potential, not all patients benefit equally from these innovative treatments due to systemic barriers, socioeconomic factors, and geographic limitations. In this interview, Dr. Cole highlights the real-world challenges faced by underserved communities and discusses potential strategies to bridge the gap in equitable care.

📍 Recorded live at the European Hematology Association (EHA) 2025 Annual Congress
#myeloma #CAR_T #bispecifics #healthequity #EHA2025 #CraigColeMD #multipmyeloma #cancerdisparities #celltherapy

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Видео Disparities in Accessing CAR-T and Bispecific Antibody Therapies | Craig Cole, MD | EHA 2025 канала HealthTree University for Multiple Myeloma